London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Is there any effect of recombinant growth hormone treatment on intraocular pressure in children with growth hormone deficiency?

Poster Details

First Author: E.Erdem TURKEY

Co Author(s):    G. Simdivar   F. Gurbuz   B. Yuksel   M. Yagmur   R. Ersoz  

Abstract Details

Purpose:

To evaluate the effect of recombinant growth hormone (rhGH) treatment on intraocular pressure (IOP) in children during one year follow-up.

Setting:

Cukurova University Faculty of Medicine, Adana/Turkey

Methods:

This is an observational cohort study including comparison of IOPs before and 6th, and 12th months of rhGH treatment in children with growth hormone deficiency. All patients underwent a complete ocular examination including IOP measurements with Goldmann applanation tonometry. Ultrasonic pachymetry also performed in order to calculate of corrected IOP. Only one eye of patients was selected randomly. Automatized visual field analyses were performed baseline and last visit. Baseline IOP values compared with age-matched controls.

Results:

The mean age was 11.4 ± 2 years (7-14 years) of 21 patients (9 male, 12 female). All children were treated for 12 months, and mean rhGH dose was 0.03 mg/kg/d. Mean baseline IOP was 12.6 in control group and 13.2 in patient group (p>0.05). At follow-up, mean IOP was 14.4 mmHg at 6th month (p>0.05), and 15.8 mmHg at 12th month (p=0.04). There was no pathologic changes at the optic nerve and visual field analyses during follow-up.

Conclusions:

The results showed that IOP seems positively correlated with the treatment duration. IOP monitoring may be necessary for patients who will start to rhGH treatment.

Financial Disclosure:

NONE

Back to Poster listing